Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

Published:2013-10 Issue:11 Volume:14 Page:1104-1111
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Calabrò Luana,Morra Aldo,Fonsatti Ester,Cutaia Ornella,Amato Giovanni,Giannarelli Diana,Di Giacomo Anna Maria,Danielli Riccardo,Altomonte Maresa,Mutti Luciano,Maio Michele

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Advances in malignant mesothelioma;Robinson;N Engl J Med,2005

2. Multidisciplinary treatment of malignant pleural mesothelioma;Ceresoli;Oncologist,2007

3. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J Clin Oncol,2003

4. Second-line treatment for malignant pleural mesothelioma;Ceresoli;Cancer Treat Rev,2010

5. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma;Jassem;J Clin Oncol,2008

Cited by 318 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Modulatory Role of Phytochemicals/Natural Products in Cancer Immunotherapy;Current Medicinal Chemistry;2024-10

2. DNA methylation status classifies pleural mesothelioma cells according to their immune profile: implication for precision epigenetic therapy;2024-08-09

3. Advances in Immunotherapy for Malignant Pleural Mesothelioma: From Emerging Strategies to Translational Insights;Open Respiratory Archives;2024-07

4. Unveiling the mechanisms and challenges of cancer drug resistance;Cell Communication and Signaling;2024-02-12

5. The future of targeting cytotoxic T-lymphocyte-associated protein-4: Is there a role?;European Journal of Cancer;2024-02